Q32 Bio
Developing therapies targeting powerful regulators of innate and adaptive immunity to rebalance the immune system in severe autoimmune and inflammatory diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD464m (Public information from Nov 2023)
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $46.0m | Series A | |
$60.0m | Series B | ||
* | $42.0m Valuation: $300m | Private Placement VC | |
| N/A | N/A | IPO | |
* | $42.0m | Post IPO Equity | |
| Total Funding | AUD229m | ||
Related Content
Recent News about Q32 Bio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Q32 Bio
Edit
ACQUISITION by Q32 Bio Nov 2023